• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Great Debates: Neoadjuvant Therapy Should be Routinely Given for High-Risk Cholangiocarcinoma.

作者信息

Tran Cao Hop S, Ferrone Cristina, Maithel Shishir K, Rocha Flavio G

机构信息

Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA, USA.

出版信息

Ann Surg Oncol. 2023 Dec;30(13):7960-7965. doi: 10.1245/s10434-023-14254-0. Epub 2023 Sep 13.

DOI:10.1245/s10434-023-14254-0
PMID:37702902
Abstract
摘要

相似文献

1
Great Debates: Neoadjuvant Therapy Should be Routinely Given for High-Risk Cholangiocarcinoma.重大辩论：高危胆管癌应常规给予新辅助治疗。
Ann Surg Oncol. 2023 Dec;30(13):7960-7965. doi: 10.1245/s10434-023-14254-0. Epub 2023 Sep 13.
2
ASO Author Reflections: Accuracy of Preoperative Staging and Downstaging After Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma.ASO作者反思：可切除性肝内胆管癌新辅助治疗后术前分期及降期的准确性
Ann Surg Oncol. 2023 Aug;30(8):4809-4810. doi: 10.1245/s10434-023-13485-5. Epub 2023 Apr 12.
3
[Efficacy of neoadjuvant chemoradiation therapy for clinical Stage II cholangiocarcinoma as a preoperative diagnosis].新辅助放化疗对临床II期胆管癌作为术前诊断的疗效
Gan To Kagaku Ryoho. 2012 Nov;39(12):1945-7.
4
Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma.肝外（中段和远端）胆管癌的新型多模态治疗序贯方案。
Ann Surg Oncol. 2013 Apr;20(4):1230-9. doi: 10.1245/s10434-012-2648-0. Epub 2012 Oct 12.
5
A case of giant intrahepatic cholangiocarcinoma with pathological complete remission after neoadjuvant therapy.1例新辅助治疗后病理完全缓解的巨大肝内胆管癌病例。
Asian J Surg. 2023 Apr;46(4):1832-1833. doi: 10.1016/j.asjsur.2022.10.058. Epub 2022 Nov 1.
6
[A resected case of hilar cholangiocarcinoma treated with neoadjuvant chemoradiation therapy].[1例经新辅助放化疗治疗的肝门部胆管癌切除病例]
Gan To Kagaku Ryoho. 2013 Nov;40(12):1756-8.
7
Hilar cholangiocarcinoma and liver transplantation.肝门部胆管癌与肝移植
Transplantation. 2009 Aug 15;88(3):299-300. doi: 10.1097/TP.0b013e3181adca5a.
8
Radioembolization with yttrium as neoadjuvant therapy in initially unresectable intrahepatic cholangiocarcinoma.钇放射性栓塞术作为初始不可切除肝内胆管癌的新辅助治疗
Cir Esp (Engl Ed). 2023 Feb;101(2):143-145. doi: 10.1016/j.cireng.2022.09.005. Epub 2022 Sep 5.
9
Intrahepatic cholangiocarcinoma: a worthy challenge.肝内胆管癌：一项值得应对的挑战。
Cancer J. 2009 May-Jun;15(3):255-6. doi: 10.1097/PPO.0b013e3181a7467d.
10
Distal cholangiocarcinoma.远端胆管癌
Surg Oncol Clin N Am. 2014 Apr;23(2):265-87. doi: 10.1016/j.soc.2013.11.001.

引用本文的文献

1
Annals of Surgical Oncology Practice Guidelines Series: Management of Primary Liver and Biliary Tract Cancers.《外科肿瘤学年鉴实践指南系列：原发性肝脏和胆道癌的治疗》
Ann Surg Oncol. 2023 Dec;30(13):7935-7949. doi: 10.1245/s10434-023-14255-z. Epub 2023 Sep 11.

本文引用的文献

1
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗联合吉西他滨和顺铂与单纯吉西他滨和顺铂治疗晚期胆道癌患者的比较（KEYNOTE-966）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.
2
Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.辅助吉西他滨加顺铂与卡培他滨治疗淋巴结阳性肝外胆管癌：STAMP 随机试验。
Hepatology. 2023 May 1;77(5):1540-1549. doi: 10.1097/HEP.0000000000000046. Epub 2023 Jan 3.
3
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.新辅助-辅助或仅辅助派姆单抗治疗晚期黑色素瘤。
N Engl J Med. 2023 Mar 2;388(9):813-823. doi: 10.1056/NEJMoa2211437.
4
Optimizing Circulating Tumour DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma: Diagnosis, Screening, Minimal Residual Disease Detection and Treatment Response Monitoring.优化围手术期循环肿瘤 DNA 在肝内胆管癌中的应用：诊断、筛查、微小残留病灶检测和治疗反应监测。
Ann Surg Oncol. 2023 Jun;30(6):3849-3863. doi: 10.1245/s10434-023-13126-x. Epub 2023 Feb 20.
5
Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes?新辅助化疗治疗高危肝内胆管细胞癌——病理缓解是否意味着更好的结局？
HPB (Oxford). 2023 Apr;25(4):472-480. doi: 10.1016/j.hpb.2023.01.011. Epub 2023 Jan 24.
6
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.辅助 S-1 对比观察用于可切除胆管癌（JCOG1202，ASCOT）：一项多中心、开放标签、随机、对照、III 期临床试验。
Lancet. 2023 Jan 21;401(10372):195-203. doi: 10.1016/S0140-6736(22)02038-4.
7
Predictors, Patterns, and Impact of Adequate Lymphadenectomy in Intrahepatic Cholangiocarcinoma.肝内胆管癌充分淋巴结清扫的预测因素、模式及影响
Ann Surg Oncol. 2023 Apr;30(4):1966-1977. doi: 10.1245/s10434-022-13044-4. Epub 2023 Jan 9.
8
The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients.切除后辅助治疗中治疗延误的影响：胆管癌患者的分析
J Gastrointest Cancer. 2023 Jun;54(2):492-500. doi: 10.1007/s12029-022-00820-4. Epub 2022 Apr 20.
9
How I treat biliary tract cancer.我如何治疗胆道癌。
ESMO Open. 2022 Feb;7(1):100378. doi: 10.1016/j.esmoop.2021.100378. Epub 2022 Jan 13.
10
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.改良FOLFIRINOX方案与CISGEM方案治疗晚期胆管癌患者的疗效比较（PRODIGE 38 AMEBICA）：一项随机II期研究
J Clin Oncol. 2022 Jan 20;40(3):262-271. doi: 10.1200/JCO.21.00679. Epub 2021 Oct 18.